FDA Brief

Warning letters Devices

FDA warning letter to

Flawless Beauty and Skin

MediumIssued Aug 5, 2022Posted Oct 4, 2022Center for Devices and Radiological Health

FDA says Flawless Beauty and Skin marketed unapproved microneedling devices and failed to register as an initial importer.

What happened

FDA inspected the firm at its Ocean, NJ facility from November 16, 2021 through January 19, 2022 and later reviewed its website on July 26, 2022. FDA said the company was an initial importer (first U.S. importer) of Relumins derma pens, dermastampers, dermarollers, MESOpower pen and needle modules, and an Intense Glow Beauty Care Tool. FDA found the products were adulterated (illegally marketed) because no premarket approval or investigational device exemption was in effect, and misbranded (illegally labeled) because no 510(k) notice was provided and the firm had not registered or listed for fiscal year 2022.

What FDA found

  1. FDA says the devices were illegally marketed without FDA approval to market them or an allowed research-use exemption.

    FD&C Act § 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); § 515(a), 21 U.S.C. § 360e(a); § 520(g), 21 U.S.C. § 360j(g)
  2. FDA says the firm did not file the required 510(k) premarket notification (a request for FDA clearance).

    FD&C Act § 502(o), 21 U.S.C. § 352(o); § 510(k), 21 U.S.C. § 360(k)
  3. FDA says website claims that the tools penetrate skin or affect skin structure and function make them medical devices.

    FD&C Act § 201(h), 21 U.S.C. § 321(h); § 201(h)(3)
  4. FDA says the firm did not annually register as an initial importer or list its devices for fiscal year 2022.

    FD&C Act § 510, 21 U.S.C. § 360; 21 CFR 807.3(g); 21 CFR 807.20(a)(5); § 510(p)
  5. FDA says the devices were not made in a registered establishment and were not on a required device list.

    FD&C Act § 502(o), 21 U.S.C. § 352(o); § 510(j), 21 U.S.C. § 360(j)

What FDA wants

FDA asks the firm to respond in writing within 15 business days with the specific steps taken to address the violations, prevent recurrence, and documentation of corrections; if the firm believes it is compliant, it should explain why with supporting information.

Who should pay attention

  • distributors and retailers of microneedling devices
  • importers of aesthetic devices
  • brands selling derma pens, rollers, or stampers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  3. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  4. ProDx Health

    FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.

    High risk